WHY NOW
Verified recent context
0 itemsNo verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.
WHY THIS GROUP EXISTS
Shared filing context
13/15 members coveredModerate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across BXMT, CHRW, HII, LKQ, MKTX, MSFT, PFSI, PHIN, WHD.
credit / rates affecting interest expense
“The accounting method for reflecting the Notes on our condensed consolidated balance sheet, accruing interest expense for the Notes and reflecting the underlying shares of our common stock in our reported diluted earnings per share may adversely affect our reported earnings and financial condition.”
ALNY 10-Q · 2026-07-30
restructuring affecting expense
“Personnel expenses increased primarily due to higher restructuring charges related to workforce reductions.”
CHRW 10-Q · 2026-07-31
demand / volume
“nded December 31, 2025, compared to the year ended December 31, 2024, primarily due to growth from AMVUTTRA revenues driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., which was partially offset by a decreased number of patients on ONPATTRO, and due to growth from an increased number of patients on GIVLAARI and OXLUMO.”
ALNY 10-K · 2026-02-12
CONFIRMATION NETWORK
Outsiders and cross-asset links
0 outsiders confirmingALNY → UVXYPositive historical lead/lag · strength 0.26
ALNY → HYGInverse historical lead/lag · strength -0.14
Filing-linked outsiders test whether the move is spreading beyond the established cohort.
No high-confidence filing-linked outsiders are available for this group yet.